Neuphoria Therapeutics Inc. Increase (Decrease) in Accounts Payable
Neuphoria Therapeutics Inc. (NEUP) reported Increase (Decrease) in Accounts Payable of -$768.78 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$241.60K, a 141.61% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $106.48K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$850.02K, a 515.31% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $216.36K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2026 was -$768.78K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2025 was -$917.66K, a 214.08% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2024 was $804.37K, a 114.97% increase from fiscal 2023.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2023 was $374.18K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$241.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$135.13K derived: sum of 2 quarters · filed 2026-09-18 | -$985.14K derived: sum of 3 quarters · filed 2026-09-18 | -$768.78K 10-K · filed 2026-09-18 |
| 2026-03-31 | $106.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$743.54K derived: sum of 2 quarters · filed 2026-05-15 | -$527.18K 10-Q · filed 2026-05-15 | $53.48K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$850.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$633.66K 10-Q · filed 2026-02-17 | -$53.00K derived: sum of 3 quarters · filed 2026-09-18 | -$838.33K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $216.36K 10-Q · filed 2025-11-14 | $797.02K derived: sum of 2 quarters · filed 2026-09-18 | $11.69K derived: sum of 3 quarters · filed 2026-09-18 | $216.36K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $580.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$204.67K derived: sum of 2 quarters · filed 2026-09-18 | $5.00 derived: sum of 3 quarters · filed 2026-09-18 | -$917.66K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$785.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$580.66K derived: sum of 2 quarters · filed 2026-05-15 | -$1.50M 10-Q · filed 2026-05-15 | $165.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $204.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$713.00K 10-Q · filed 2026-02-17 | $950.33K derived: sum of 3 quarters · filed 2026-02-17 | $84.77K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$917.67K 10-Q · filed 2025-11-14 | $745.65K derived: sum of 2 quarters · filed 2025-11-14 | -$119.91K derived: sum of 3 quarters · filed 2025-11-14 | -$993.91K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $797.76K derived: sum of 2 quarters · filed 2025-09-29 | -$76.24K derived: sum of 3 quarters · filed 2025-09-29 | $804.37K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$865.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$1.74M derived: sum of 2 quarters · filed 2025-05-20 | -$858.95K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$874.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $6.61K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $880.61K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $374.18K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |